3 Australian AI Healthcare Stocks With Revenue Growth Up To 49%

Rising global bond yields have pushed borrowing costs higher for governments and companies, which puts pressure on healthcare budgets and hospital funding. Australian AI healthcare stocks sit at an interesting crossroads. Their tools aim to cut waste, speed up diagnoses, and help clinicians do more with less. This article breaks down three stocks from our AI healthcare screener that could benefit if cost control becomes the main priority.

The three ASX AI healthcare stocks in this article are only a starter set, and the full screen surfaced 4 more companies with equally compelling stories that are not covered below. To go deeper into this theme, analyze and compare candidates directly in the Transformative Artificial intelligence (AI) Healthcare Stocks screener

ImExHS (ASX:IME)

ImExHS blends cloud-based medical imaging software with outsourced and teleradiology services, feeding AI tools with labeled scans and workflows. The group generated about A$21 million from radiology and A$10 million from software, and carries a market value near A$18 million.

ImExHS gives the AI healthcare theme real-world traction by handling both the imaging software and radiology services that supply the data AI models need. This context sets up the latest management commentary as an important signal for where the next phase of progress might come from.

"They also understand the challenge now is to drive the software sales and revenue much faster in 2026."

For investors, what happens when one key piece of that AI-driven business model begins to scale faster than the rest could matter a lot.

When one engine of the model starts to decouple from the rest, the full narrative for ImExHS shows how that shift could re-rate expectations and spell out the key pressure points.

Singular Health Group (ASX:SHG)

Singular Health Group builds 3DICOM and Volumetric Rendering tools that convert 2D CT, MRI, and PET scans into 3D models, with AI in the Cloud applying models to that imaging data. The business generated about A$1.9 million from 3D medical software and has a market value near A$57 million.

Singular Health Group provides direct exposure to AI-driven medical imaging, where 3D reconstruction and cloud-based analysis can sharpen diagnostics but still sit on early-stage economics. The stock trades on relatively high sales multiples and ongoing losses, so future sentiment around margins could shift quickly if a single pressure point moves in an unfavourable direction.

Those pressure points are already shifting, so it helps to see how they line up within the analysis report for Singular Health Group before sentiment really starts to accelerate.

Artrya (ASX:AYA)

Artrya uses its Salix AI software to read coronary CT scans and flag patients at risk of heart attack, with all A$0.03 million in recent revenue coming from this AI-driven CCTA analysis work in Australia and the stock valued at about A$580 million.

For this screener, Artrya matters because Salix is not a side project. It is the whole commercial focus, tying every dollar of early revenue to AI-driven cardiac diagnostics and turning clinical evidence into the real test of whether that ambition can scale.

"The SAPPHIRE multicenter real world study, targeting 10,000 to 12,000 scans across six high volume US systems and led by a well known principal investigator, is set up to build clinical evidence and brand credibility."

What happens if early commercial assumptions around how quickly hospitals shift their CCTA workflows to Salix prove even slightly too optimistic?

If that timing risk matters to you, the full narrative for Artrya shows how Artrya’s thesis could accelerate or stall as real world evidence lands.

Seeking Alternatives Before Everyone Else?

Fresh ideas move first. Watch potential breakout themes gain momentum while many are still catching up. Scan curated shortlists that are under the radar for now and consider your options early.

• Spot cash generative opportunities early by running your filters through the 5 high quality undervalued stocks before shifting market attention starts closing today’s gaps.
• Target steady income ideas that aim to balance yield and resilience with the curated 3 dividend fortresses while payout levels and entry points still look reasonable.
• Consider structural technology shifts by scanning the hand picked 90 AI infrastructure stocks before infrastructure demand, pricing, and expectations move further ahead of you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com